<DOC>
	<DOC>NCT01762163</DOC>
	<brief_summary>This is a 20-week study consisting of a 12-week multicenter, randomized,double-blind adaptive study to compare efficacy and safety of Qizhitongluo Capsule,Naoxintong Capsule and placebo in the recovery phase of ischemic stroke with qi deficiency and blood stasis syndrome, and a 8-week post-treatment safety follow-up.After 312 patients complete 12 weeks of treatment there will be an interim analysis.</brief_summary>
	<brief_title>Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Age≥35 years and &lt;80 years; Diagnosis of ischemic stroke in recovery phase, according to the Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2010; Diagnosis of ischemic stroke with qi deficiency and blood stasis syndrome; The interval from the onset to recruitment was 1528 days; FM score &lt;90 or AQ＜93.8 and diagnosis of aphasia; Diagnosis of cerebral anterior circulation obstruction; 4≤ NIHSS score＜20; Patient is willing to participate voluntarily and to sign a written patient informed consent. Evidence of intracranial hemorrhage (ICH) or other cerebral diseases (eg.vascular malformation, tumor, abscess or multiple sclerosis etc.) on CT or MRI. Known history of allergy or suspected allergic to the study drugs. Liver function impairment with the value of ALT or AST over 1.5fold of normal value. Renal dysfunction with the value of serum creatinine over 1.5fold of normal value. Cerebral embolism caused by cerebral tumor, cerebral trauma, cerebral parasitosis, rheumatic heart disease, coronary heart disease or other cardiac diseases complicated with atrial fibrillation. Prestroke score on the mRS ≥2. Spaceoccupying lesions, CT or MRI revealed midline structure shift; CT revealed that massive cerebral infarction including more than one lobe of brain or over 1/3 of bloodsupply area of middle cerebral artery. Disable patients prescribed by law（blind, deaf, dumb, mental retardation, mental disorders and physical disabilities which due to other causes affect neural function deficient scale). Hemorrhagic tendency or recent severe or dangerous bleeding in 3 months. Suspected addicted into alcohol or drug abuse; with severe complications that would make the condition more complicated assessed by the investigator. Woman with pregnancy, lactation or positive result of pregnancy test, or women who want to be pregnant in recent. Patient who is participating in other trials or has been participated in other trials in recent 3 months.</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ischemic Stroke,adaptive design, randomized, double-blind</keyword>
</DOC>